Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- DIAGNOSTIC NEWS IN BRIEF
March 1, 2004
- JT Sees Pharma Business as "Next-generation Mainstay"
March 1, 2004
- Wishing to Keep AGR of 10-15% for Coming Years: Dr Tallarigo of Eli Lilly
March 1, 2004
- Sales of Daiichi's Coversyl Beginning to Slacken
March 1, 2004
- Heparinized Saline Kit Market Growing Rapidly
March 1, 2004
- BUSINESS NEWS IN BRIEF
March 1, 2004
- WEBSITE NEWS
March 1, 2004
- Artificial Hip Joint for Japanese Developed: Stryker Japan Seminar
February 23, 2004
- REGULATORY NEWS IN BRIEF
February 23, 2004
- Medical Expenditures for Elderly to Decrease 0.4% in FY2004
February 23, 2004
- GEYMS: X-ray Surgery Devices with Electrically-operated C Arm
February 23, 2004
- Medical Institutions' Profits Down, but Industry Profits Up: JMARI Report
February 23, 2004
- BrainLAB: Novalis Body X-Ray Equipment for Radiotherapy
February 23, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 23, 2004
- Notification on Reuse of Implantable Medical Materials
February 23, 2004
- Pfizer Japan to Build Up Ophthalmology Business in Japan
February 23, 2004
- DIAGNOSTIC NEWS IN BRIEF
February 23, 2004
- Takeda's MRs Are Best to Solve Doctors' Problems: Moss Survey
February 23, 2004
- Efficiency of NHI Price System Increased: Dr Yazaki
February 23, 2004
- BUSINESS NEWS IN BRIEF
February 23, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…